FDA Approves CDK4/6 Inhibitor, Kisqali, to Treat Type of Metastatic Breast Cancer
News
The U.S. Food and Drug Administration has approved Kisqali (ribociclib), in combination with an aromatase inhibitor as first-line treatment for post-menopausal and hormone-positive, HER2-negative metastatic breast cancer patients. The approval ... Read more